Open AccessImmunodeficient patient experience of emergency switch from intravenous to rapid push subcutaneous immunoglobulin replacement therapy during coronavirus disease 2019 shielding
Author(s) -
Clare Morgan,
Stephen Jolles,
Mark J. Ponsford,
K. T. Evans,
Emily Carne
Publication year - 2022
Publication title -
current opinion in allergy and clinical immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.94
H-Index - 84
eISSN - 1528-4050
pISSN - 1473-6322
DOI - 10.1097/aci.0000000000000864
Subject(s) - medicine , covid-19 , disease , infectious disease (medical specialty)
Welsh immunodeficient patients on immunoglobulin replacement therapy (IgRT) who were considered high risk for severe coronavirus disease 2019 (COVID-19) were directed to shield. Consequently, patients receiving hospital-based intravenous immunoglobulin (IVIg) quickly transitioned to home-based self-administered subcutaneous immunoglobulin (SCIg). This evaluation aimed to assess patients' perceptions and experiences and laboratory outcomes of emergency IgRT transition during COVID-19.